TrialSignal transduction and targeted therapy2025

Efficacy, safety and exploratory analysis of neoadjuvant tislelizumab (a PD-1 inhibitor) plus nab-paclitaxel followed by epirubicin/cyclophosphamide for triple-negative breast cancer: a phase 2 TREND trial.

Qiang Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.